VCM
BMRN icon

Voleon Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Voleon Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$943K Sell
16,478
-15,596
-49% -$854K 0.02% 485
2026
Q1 		$1.81M Sell
32,074
-20,680
-39% -$1.21M 0.04% 348
2025
Q4 		$3.14M Sell
52,754
-13,027
-20% -$709K 0.07% 275
2025
Q3 		$3.56M Buy
65,781
+61,662
+1,497% +$3.53M 0.09% 232
2025
Q2 		$226K Buy
+4,119
New +$243K 0.01% 448

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Voleon Capital Management's BMRN Position: Q2 2026 in Review

Voleon Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 49% in Q2 2026, selling an estimated $854K and leaving 16,478 shares worth $943K. The position accounts for 0.02% of the portfolio, ranked #485.

Voleon Capital Management first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.56M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Voleon Capital Management held 16,478 shares of BioMarin Pharmaceuticals worth $943K as of Q2 2026.
  • Voleon Capital Management sold 15,596 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $854K.
  • BioMarin Pharmaceuticals made up 0.02% of Voleon Capital Management's portfolio in Q2 2026, its #485 holding.
  • Voleon Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Voleon Capital Management's BioMarin Pharmaceuticals position peaked at $3.56M in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.